People news: Pfizer, Bausch & Lomb, Sanofi-Aventis, Human Genome Sciences

Share this article:
Pfizer's board of directors elected George Lorch as non-executive chairman of the board. Lorch has been an independent director since 2000 and is chairman emeritus of Armstrong Holdings, a manufacturer of flooring and ceiling materials.

Bausch & Lomb named Daniel Wechsler corporate VP and global president, pharma business. Wechsler joins Bausch & Lomb from Merck, where he was head of US strategy, commercial model innovation and business development.

Sanofi-Aventis named Dr. Elias Zerhouni president, global research and development for medicines and vaccines, and said EVP R&D Marc Cluzel, MD, PhD will resign his post but continue to advise Dr. Zerhouni, who has served as a scientific adviser to CEO Chris Viehbacher since 2009.

Human Genome Sciences named former OSI Pharmaceuticals chief Colin Goddard, PhD to its board of directors.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.